Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Gefitinib leads to complete resolution of postoperative cervical chyloma and chylothorax in a lung cancer patient.

Huang CL, Chang H, Lee JC, Dai MS.

Tumori. 2014 Mar-Apr;100(2):e49-51. doi: 10.1700/1491.16435.

PMID:
24852876
2.

Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.

Funakoshi Y, Takeuchi Y, Maeda H.

Asian Cardiovasc Thorac Ann. 2013 Aug;21(4):482-4. doi: 10.1177/0218492312462834. Epub 2013 Jul 9.

PMID:
24570539
3.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
4.

Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.

Kishi K, Nakata K, Yoshimura K.

J Thorac Oncol. 2006 Sep;1(7):733-4. No abstract available.

5.

Mediastinal chyloma after lung cancer surgery: case report.

Furukawa M, Tao H, Tanaka T, Okabe K.

J Cardiothorac Surg. 2016 Aug 2;11(1):115. doi: 10.1186/s13019-016-0522-z.

6.

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.

Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE.

J Clin Oncol. 2006 Sep 20;24(27):4517-20. No abstract available.

PMID:
16983123
7.

Lung cancer response to gefitinib, then erlotinib, then gefitinib again.

Wong AS, Seto KY, Chin TM, Soo RA.

J Thorac Oncol. 2008 Sep;3(9):1077-8. doi: 10.1097/JTO.0b013e318183afb0. No abstract available.

8.

A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.

Hotta K, Kiura K, Shirahige A, Takata S, Takigawa N, Tabata M, Watanabe H, Tanimoto M.

Acta Oncol. 2009;48(3):471-3. doi: 10.1080/02841860802425310. No abstract available.

PMID:
18855159
9.

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.

Wong AS, Soong R, Seah SB, Lim SW, Chuah KL, Nga ME, Chin TM, Soo RA.

J Thorac Oncol. 2008 Apr;3(4):400-4. doi: 10.1097/JTO.0b013e318168c801.

10.

Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.

Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W.

Clin Cancer Res. 2006 Oct 1;12(19):5659-67.

11.

Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.

Garfield D.

J Thorac Oncol. 2006 Oct;1(8):859-60. No abstract available.

12.

(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.

van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.

Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21.

PMID:
24845729
13.

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.

Yokoyama Y, Sonobe M, Yamada T, Sato M, Menju T, Aoyama A, Sato T, Chen F, Omasa M, Date H.

Int J Clin Oncol. 2015 Dec;20(6):1122-9. doi: 10.1007/s10147-015-0838-z. Epub 2015 May 8.

PMID:
25953679
14.

Brain metastasis responding to gefitinib alone.

Poon AN, Ho SS, Yeo W, Mok TS.

Oncology. 2004;67(2):174-8. Review.

PMID:
15539923
15.

First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.

Lange T, Müller-Tidow C, Serve H, Hoffknecht P, Berdel WE, Thomas M.

Oncol Rep. 2005 Dec;14(6):1539-42.

PMID:
16273252
16.

Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.

Laterza MM, Chiurazzi B, Brangi M, Riccardi F, Cartenì G.

Tumori. 2013 Jan-Feb;99(1):3e-5e. doi: 10.1700/1248.13802.

PMID:
23549019
17.

Nonpalpable supraclavicular lymph nodes in lung cancer patients: preoperative characterization with 18F-FDG PET/CT.

Sung YM, Lee KS, Kim BT, Kim S, Kwon OJ, Choi JY, Yang SO.

AJR Am J Roentgenol. 2008 Jan;190(1):246-52.

PMID:
18094319
18.

Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.

Marech I, Vacca A, Gnoni A, Silvestris N, Lorusso V.

Tumori. 2013 Sep-Oct;99(5):e241-4. doi: 10.1700/1377.15324. Review.

PMID:
24362878
19.

Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.

Hishida T, Nagai K, Mitsudomi T, Yokoi K, Kondo H, Horinouchi H, Akiyama H, Nagayasu T, Tsuboi M; Japan Clinical Oncology Group.

J Thorac Cardiovasc Surg. 2010 Nov;140(5):e69-71. doi: 10.1016/j.jtcvs.2010.06.035. Epub 2010 Aug 2. No abstract available.

20.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455

Supplemental Content

Support Center